Untitled design (34).png

OPTIMAL TREATMENT OF RETINAL DISEASE LEVERAGING NOVEL DELIVERY TECHNOLOGY

 
16.png
23.png
Everads: more effective, durable treatment for retinal diseases.
Our technology facilitates targeted, rapid delivery of therapy via the emerging suprachoroidal delivery route. Leveraging our technology, we are developing treatments to improve efficacy and reduce treatment burden, and also partnering with leading pharmaceutical and biotech companies to enable delivery of novel therapies using our technology.
About Everads
Everads is an emerging startup with novel delivery technology to treat retinal diseases via suprachoroidal administration and is developing an early-stage pipeline that leverages our technology.  Our technology enables delivery of therapy to the choroid and retina via the suprachoroidal space (SCS)…. 
 Everads News

July 2022

Everads Therapy announced today that Israel’s Innovation Authority (IIA) has awarded a grant to help fund the company’s research and development. Moshe Weinstein, Everads’ CEO, stated that “We are excited to have been awarded this competitive grant, the receipt of which is a validation of the strong business and scientific case for our technology and pipeline. The grant programs of the Israel Innovation Authority are a true catalyst for Israeli companies, and we are honored and humbled to have been chosen.”

kj.png

March 2022

Ophthalmology Times: "Suprachoroidal delivery system gets drug to the macula, posterior segment"

צילום מסך 2022-07-08 ב-15.18.28.png

June 2021

Everads Enters into Collaboration to Evaluate its Suprachoroidal Delivery Technology with a Clinical-Stage Gene Therapy Company

-  Under new collaboration, partner given opt-in right to license specific retinal targets in exchange for pre-agreed license fees, development milestones and royalties

-  Agreement follows a previously-announced option deal with a global pharmaceutical company evaluating Everads' technology

Senior Woman
Contact Us

Send us a message and we’ll get back to you shortly.

Thanks for submitting!